Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Non-Current Deferred Tax Liability (2023 - 2025)

Rein Therapeutics filings provide 3 years of Non-Current Deferred Tax Liability readings, the most recent being $1.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Deferred Tax Liability fell 40.18% year-over-year to $1.1 million, compared with a TTM value of $1.1 million through Dec 2025, down 40.18%, and an annual FY2025 reading of $1.1 million, down 40.18% over the prior year.
  • Non-Current Deferred Tax Liability hit $1.1 million in Q4 2025 for Rein Therapeutics, down from $1.8 million in the prior quarter.
  • The five-year high for Non-Current Deferred Tax Liability was $3.3 million in Q4 2023, with the low at $1.1 million in Q4 2025.
  • Median Non-Current Deferred Tax Liability over the past 3 years was $1.8 million (2024), compared with a mean of $2.4 million.
  • The sharpest move saw Non-Current Deferred Tax Liability plummeted 46.72% in 2024, then plummeted 40.18% in 2025.
  • Year by year, Non-Current Deferred Tax Liability stood at $3.3 million in 2023, then crashed by 46.72% to $1.8 million in 2024, then crashed by 40.18% to $1.1 million in 2025.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods came in at $1.1 million, $1.8 million, and $1.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.